Pharmacokinetics of Biotech Products MCQs With Answer

Introduction: Pharmacokinetics of Biotech Products MCQs With Answer is a focused quiz series designed for M.Pharm students studying Advanced Biopharmaceutics & Pharmacokinetics (MIP 201T). The questions explore key concepts unique to biologics—monoclonal antibodies, recombinant proteins, peptides and other large molecules—highlighting absorption via lymphatics, distribution influenced by FcRn, nonlinear clearance from target-mediated drug disposition (TMDD), immunogenicity effects, and strategies such as PEGylation and Fc-engineering to modify PK. This set emphasizes mechanistic understanding, PK/PD relationships, population approaches, and analytical considerations crucial for designing, dosing and evaluating biotech therapeutics in preclinical and clinical development.

Q1. Which pathway is the primary route of systemic absorption after subcutaneous administration of large biologic molecules?

• Liver portal vein transport
• Transcellular diffusion across capillary endothelium
• Lymphatic uptake and transport
• Direct absorption into the systemic arterial circulation

Correct Answer: Lymphatic uptake and transport

Q2. Neonatal Fc receptor (FcRn) primarily affects which pharmacokinetic parameter of IgG monoclonal antibodies?

• Volume of distribution in central compartment
• Renal filtration rate
• Serum half-life through recycling and protection from lysosomal degradation
• Rate of proteolytic cleavage in the gut

Correct Answer: Serum half-life through recycling and protection from lysosomal degradation

Q3. Target-mediated drug disposition (TMDD) often results in what characteristic dose–exposure relationship?

• Linear increase in clearance with dose
• Saturable (nonlinear) clearance at low to moderate concentrations
• Constant bioavailability independent of dose
• Increased renal excretion at high doses

Correct Answer: Saturable (nonlinear) clearance at low to moderate concentrations

Q4. Which modification is commonly used to increase the plasma half-life of therapeutic proteins by reducing renal clearance?

• Glycosylation removal
• PEGylation
• Increasing hydrophobicity
• Conjugation with a small peptide tag

Correct Answer: PEGylation

Q5. Anti-drug antibodies (ADAs) can alter PK of biologics by which of the following mechanisms?

• Increasing gastrointestinal absorption
• Promoting rapid renal filtration of the drug
• Forming immune complexes that increase clearance or alter distribution
• Enhancing FcRn recycling to prolong half-life

Correct Answer: Forming immune complexes that increase clearance or alter distribution

Q6. For monoclonal antibodies, which compartment model often best describes plasma concentration-time profiles when target binding and distribution are moderate?

• One-compartment model with first-order absorption and elimination
• Two-compartment model with linear elimination
• Three-compartment model with zero-order absorption
• Physiologically based model with no distribution phase

Correct Answer: Two-compartment model with linear elimination

Q7. Which physicochemical property most strongly limits the oral bioavailability of large peptide and protein therapeutics?

• High lipophilicity facilitating membrane crossing
• Low molecular weight enhancing diffusion
• Proteolytic degradation and poor permeability across the intestinal epithelium
• Excessive solubility in gastric fluids

Correct Answer: Proteolytic degradation and poor permeability across the intestinal epithelium

Q8. In population pharmacokinetics for biologics, which covariate is most likely to explain interindividual variability in clearance?

• Patient hair color
• Body weight or body surface area
• Time of day drug is administered
• Tablet excipient composition

Correct Answer: Body weight or body surface area

Q9. Which mechanism is a major route of elimination for monoclonal antibodies?

• CYP3A4-mediated hepatic metabolism
• Glomerular filtration as intact molecule
• Cellular uptake followed by proteolytic catabolism in lysosomes
• Biliary excretion of unchanged antibody

Correct Answer: Cellular uptake followed by proteolytic catabolism in lysosomes

Q10. Fc-engineering to increase antibody affinity for FcRn at acidic pH is intended to achieve which pharmacokinetic outcome?

• Decrease tissue penetration
• Increase renal clearance
• Extend systemic half-life by enhanced recycling
• Accelerate receptor-mediated endocytosis into target cells

Correct Answer: Extend systemic half-life by enhanced recycling

Q11. PEGylation can influence which of the following besides half-life?

• Decrease molecular weight
• Reduce immunogenicity and alter distribution by increasing hydrodynamic radius
• Increase enzymatic degradation rate
• Promote receptor-mediated uptake into hepatocytes

Correct Answer: Reduce immunogenicity and alter distribution by increasing hydrodynamic radius

Q12. Which analytical approach is most appropriate for quantifying free versus total drug concentration when ADAs may be present?

• Using a single noncompetitive ligand-binding assay without dissociation step
• Measuring only total protein by mass spectrometry without separation
• Employing assays that can distinguish free drug from ADA-bound drug, such as acid dissociation ligand-binding assays
• Relying solely on pharmacodynamic markers instead of drug assays

Correct Answer: Employing assays that can distinguish free drug from ADA-bound drug, such as acid dissociation ligand-binding assays

Q13. Allometric scaling of biologic clearance between species often requires consideration of which additional factor compared to small molecules?

• Only body weight is sufficient for accurate scaling
• Species differences in target expression, FcRn affinity and proteolytic pathways
• Exclusive reliance on glomerular filtration rate differences
• Assumption of identical plasma protein binding across species

Correct Answer: Species differences in target expression, FcRn affinity and proteolytic pathways

Q14. Which statement best describes the concept of ‘bioavailability’ for subcutaneously administered monoclonal antibodies?

• Bioavailability is always 100% for subcutaneous biologics
• Bioavailability reflects the fraction reaching systemic circulation and is often reduced by proteolysis and incomplete lymphatic uptake
• Bioavailability is determined solely by hepatic first-pass metabolism
• Bioavailability is irrelevant for biologics because they are large molecules

Correct Answer: Bioavailability reflects the fraction reaching systemic circulation and is often reduced by proteolysis and incomplete lymphatic uptake

Q15. Nonlinear pharmacokinetics of a therapeutic antibody becoming dose-proportional at high doses is likely due to what?

• Saturation of nonspecific proteolytic pathways
• Saturation of target-mediated elimination leading to linear (parallel) clearance at high concentrations
• Enhanced renal filtration at high concentrations
• Induction of metabolic enzymes in the liver

Correct Answer: Saturation of target-mediated elimination leading to linear (parallel) clearance at high concentrations

Q16. Which PK/PD modeling approach is most appropriate when high-affinity target binding causes complex disposition and pharmacologic effect?

• Empirical one-compartment model without target binding
• TMDD (target-mediated drug disposition) models linking target binding to disposition and effect
• Simple Emax model ignoring concentrations
• Noncompartmental analysis only

Correct Answer: TMDD (target-mediated drug disposition) models linking target binding to disposition and effect

Q17. Glycosylation of monoclonal antibodies can influence which of the following pharmacokinetic or pharmacodynamic properties?

• Only oral absorption
• Fcγ receptor binding, clearance by immune cells, and effector functions such as ADCC
• Renal glomerular filtration size threshold only
• Elimination solely via hepatic CYP enzymes

Correct Answer: Fcγ receptor binding, clearance by immune cells, and effector functions such as ADCC

Q18. Therapeutic proteins with molecular weight below approximately 60 kDa are more likely to be eliminated by which process compared to larger antibodies?

• Endosomal FcRn recycling
• Renal filtration leading to urinary excretion
• Exclusive biliary secretion
• Transcytosis across the blood-brain barrier

Correct Answer: Renal filtration leading to urinary excretion

Q19. Which clinical strategy can be used to mitigate the impact of immunogenicity on biologic pharmacokinetics?

• Switching from intravenous to oral dosing
• Pre-treatment immunosuppression, dosing regimen adjustments or engineering humanized sequences to reduce ADA formation
• Increasing dosing frequency without monitoring
• Reducing formulation pH to below physiological levels

Correct Answer: Pre-treatment immunosuppression, dosing regimen adjustments or engineering humanized sequences to reduce ADA formation

Q20. When designing first-in-human dosing for a monoclonal antibody, which preclinical data are most critical for predicting human pharmacokinetics?

• Only in vitro potency with no in vivo data
• Pharmacokinetic data in relevant species, target expression differences, FcRn binding and in vitro target affinity to inform PK/PD and allometric scaling
• Human case reports only
• Stability in tablet formulations

Correct Answer: Pharmacokinetic data in relevant species, target expression differences, FcRn binding and in vitro target affinity to inform PK/PD and allometric scaling

Download